Jefferies Cuts Numbers on ViroPharma (VPHM) But Says Buy on "Overreaction"

Article Stock Quotes (1) Comments (0)

Jefferies cut estimates and its price target on ViroPharma (NASDAQ: VPHM) from $37 to $33 but is keeping its Buy rating after the FDA approved three generic versions of Vancocin and responded to VPHM’s citizen petition, detailing their denial of 3-year exclusivity for Vancocin.

"We would be buyers on today's overreaction, as Cinryze is the critical driver of the VPHM story," the analyst said.

For an analyst ratings summary and ratings history on ViroPharma click here. For more ratings news on ViroPharma click here.

Shares of ViroPharma closed at $22.44 yesterday, with a 52 week range of $14.62-$33.17.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Needham & Company Lifts Numbers on Marvell (MRVL) on Solid Results
• Wells Fargo Boosts Price Target on Pandora (P), Maintains Outperform
• Hewlett-Packard (HPQ) Q2 Performance Wins Praise on Wall Street; Jefferies Raises to Hold

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?